New artery-delivered combo shows promise against bone cancer
NCT ID NCT06562673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new approach for osteosarcoma (bone cancer) in 10 patients aged 12-40. The treatment combined standard chemotherapy with a targeted drug (Endostar) and cisplatin delivered directly into the artery supplying the tumor. The goal was to see if this method is safe and increases tumor cell death before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital,
Shanghai, 200233, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill stall advanced sarcomas?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- New database aims to reduce bone cancer surgery risks
- Experimental vaccine fights sarcoma with Patient's own immune cells